姜兴武

姜兴武

青年副研究员 

江湾校区化学/高分子楼B6074

联系方式:xwjiang@fudan.edu.cn

教育和工作经历

  • 2021/02-至今, 复旦大学,材料科学系,青年副研究员

  • 2019/03-2021/01,同济大学,医学院,博士后

  • 2013/09-2019/01,华东师范大学,生命科学学院,博士学位

  • 2009/09-2013/06,西北农林科技大学,动物科技学院,学士学位

研究方向

  • 1.新型无机非金属材料的合成及其抗肿瘤应用研究;

  • 2.新型功能材料用于肝脏代谢类疾病研究。

学术论文

1. Yang Liu, Shaojie Zhai, Xingwu Jiang*, Yanyan Liu, Kun Wang, Chaochao Wang, Meng Zhang, Xuanyong Liu*, Wenbo Bu*. Intracellular mutual promotion of redox homeostasis regulation and iron metabolism disruption for enduring chemodynamic therapy. [J]. Advanced Functional Materials, 2021, 2010390.

2. Yifei Yin#, Xingwu Jiang#, Liping Sun#, Hongyan Li, Chunxia Su, Yan Zhang, Guang Xu, Xiaolong Li, Chongke Zhao, Yu Chen*, Huixiong Xu*, Kun Zhang*. Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma[J]. Nano Today, 2021, 36: 101009.

3.BeiEr Jiang#, Xingwu Jiang#, Qiansen Zhang, Qiuwen Liang, Zi-Liang Qiu, Xiang-Bai Sun, Jun-Jie Yang, Si Chen, Chunyang Yi, Xiaolei Chai, Mingyao Liu, Li-Fang Yu*, Weiqiang Lu*, Han-Kun Zhang*.From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis[J]. Journal of Medicinal Chemistry, 2021 Jan 14;64(1):385-403.

4. Xingwu Jiang#, Si Chen#, Qiansen Zhang, Chunyang Yi, Jiacheng He, Xiyun Ye, Mingyao Liu, Weiqiang Lu*. Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis[J]. Phytomedicine.2020, Feb;67:153160.

5. XingWu Jiang#, BeiEr Jiang#, Hao Liu, ZhiTao Liu, LongLong Hu, Mingyao Liu, Weiqiang Lu, HanKun Zhang, Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists [J].European Journal of Medicinal Chemistry, 2018 Oct 5;158:123-133.

6. Xingwu Jiang#, Weiqiang Lu#, Xiaoyang Shen#, Quan Wang, Jing Lv, Mingyao Liu, Feixiong Cheng*, Zhongming Zhao*, Xiufeng Pang*. Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy [J]. JCI insight, 2018, 3(11).